IP Library Granted Patent US 8,883,741
Granted Patent B2
US 8,883,741 · App. 13/376,023 · Granted Nov 11, 2014

Stimulator of genital, sexual and reproductive function

Inventors: Nikolay Fedorovich Myasoedov (Moscow, RU); Alim Vasilievich Nemersky (Moscow, RU); Mikhail Alexandrovich Mogutov (Moscow, RU); Tatiyana Nikolaevna Sollertinskaya (Saint Petersburg, RU); Mstislav Vladilenovich Shoroshov (Saint Petersburg, RU); Dmitry Viktorovich Golikov (Moscow, RU)
Assignee: Bio Peptid Company Limited
A61K38/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,741
App. No.
13/376,023
Granted
Nov 11, 2014
Kind
B2
Abstract

The invention relates to a novel agent having an influence on the genital, sexual and reproductive function of mammals and human beings. More specifically, the invention relates to the use of a heptapeptide of the general formula (I) Thr-Lys-Pro-Arg-Pro-Gly-Pro (SEQ ID NO: 1) as a stimulator of the genital, sexual and reproductive function of mammals and human beings. The invention widens the range of agents available for stimulating the genital, sexual and reproductive function of mammals and human beings.

Claims (9)

1. A method for stimulating genital, sexual, or reproductive function in a mammal in need thereof comprising administering to said mammal a heptapeptide having general formula (I): Thr-Lys-Pro-Arg-Pro-Gly-Pro (SEQ ID NO: 1).

2. The method of claim 1 , wherein the mammal is human.

3. The method of claim 1 , wherein the mammal has a condition selected from the group consisting of sexual dysfunctions not caused by organic disorders or diseases, the absence or loss of sexual attraction, aversion to sexual intercourse, absence of sexual pleasure, and orgasmic dysfunction.

4. The method of claim 1 , comprising administering the heptapeptide intranasally for at least 10 days.

5. The method of claim 1 , comprising administering the heptapeptide intranasally for at least 15 days.

6. A method for treating a condition in a mammal in need of such treatment comprising administering to said mammal a heptapeptide having general formula (I): Thr-Lys-Pro-Arg-Pro-Gly-Pro (SEQ ID NO: 1), wherein the condition is selected from the group consisting of sexual dysfunctions not caused by organic disorders or diseases, the absence or loss of sexual attraction, aversion to sexual intercourse, absence of sexual pleasure, and orgasmic dysfunction.

7. The method of claim 6 , wherein the mammal is human.

8. The method of claim 7 , comprising administering the heptapeptide intranasally for at least 10 days.

9. The method of claim 7 , comprising administering the heptapeptide intranasally for at least 15 days.

Assignments (3)
CHANGE OF NAME Recorded Jun 14, 2021
From: OVOCA BIO (RUSSIA) LIMITED
To: OVB (IRELAND) LIMITED
Reel/Frame 056532/0556 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2021
From: "BIO PEPTID" COMPANY LIMITED
To: OVOCA BIO (RUSSIA) LIMITED
Reel/Frame 055107/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2011
From: MYASOEDOV, NIKOLAY FEDOROVICH; NEMERSKY, ALIM VASILIEVICH; MOGUTOV, MIKHAIL ALEXANDROVICH; SOLLERTINSKAYA, TATIYANA NIKOLAEVNA; SHOROSHOV, MSTISLAV VLADILENOVICH; GOLIKOV, DMITRY VIKTOROVICH
To: <<BIO PEPTID>> COMPANY LIMITED
Reel/Frame 027325/0381 →
Priority Claims (1)
RU 2009121281 · Jun 4, 2009 · national
Continuity (1)
Related Publication 20120129791A1 · May 24, 2012